På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Dorte Dannemann, hjælp af denne formular.

29 Nov 2017

YmAbs Announces Closing of $30 Million Extension of Private Equity Placement

Common stock placement extended to a total of $80 million as Sofinnova Ventures and Scopia Capital Management are added to Y-mAbs’ list of institutional shareholders

Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that, further to its press release dated October 24, 2017, the Company has completed an extended closing of an additional $30 million in a private equity placement, adding institutional investors Sofinnova Ventures and Scopia Capital Management to its list of shareholders. Together, with the $50 million raised in the first closing, the Company has now raised $80 million pursuant to this private placement round.

The proceeds of the financing will be used to advance the development of YmAbs portfolio of late-stage oncology compounds, establish sales and marketing capabilities, and bolster general working capital. The financing will strengthen the Company’s balance sheet and position it for continued progress as it initiates and completes additional clinical trials targeting a variety of cancers.


  • PR YmAbs Second Closing 29Nov2017

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or 28895854

Copyright 2017 Danskbiotek. All rights reserved.